ITEOS THERAPEUTICS INC. overview

- Multiple TIGIT clinical data readouts anticipated throughout 2025, including >400 patients from two Phase 2 trials and one Phase 1/2 assessing belrestotug + dostarlimab in 1L NSCLC and 1L HNSCC - EOS-984 Phase 1 monotherapy and PD-1 combination data anticipated in 2H25 - EOS-215, a potential best-in-class anti-TREM2 monoclonal antibody, IND submission anticipated in 1Q25 - Cash balance and investment balance of $683.9 million as of September 30, 2024 expected to provide runway through 2027...

WATERTOWN, Mass. and GOSSELIES, Belgium, Jan. 08, 2025 (GLOBE NEWSWIRE) -- iTeos Therapeutics, Inc. (Nasdaq: ITOS), a clinical-stage biopharmaceutical company pioneering the discovery and development of a new generation of immuno-oncology therapeutics for patients, today announced that Michel Detheux, Ph.D., President and Chief Executive Officer, will present at the 43 rd Annual J.P. Morgan Healthcare Conference being held in San Francisco, CA on Wednesday, January 15, 2025 at 7:30 AM PST (10:30...

- Inupadenant + carboplatin/pemetrexed in Phase 2 A2A-005 trial demonstrated a 63.9% overall response rate (ORR) and a median PFS of 7.7 months for all evaluable patients across the cohorts - Recommended Phase 2 dose (RP2D) of inupadenant 80mg + carboplatin/pemetrexed demonstrated 73.3% ORR, with 64.6% of patients achieving landmark 6-month PFS - Inupadenant + carboplatin/pemetrexed safety profile was manageable and tolerable, with no dose-dependent toxicity observed - Inupadenant deprioritized...

WATERTOWN, Mass. and GOSSELIES, Belgium, Nov. 26, 2024 (GLOBE NEWSWIRE) -- iTeos Therapeutics, Inc. (Nasdaq: ITOS), a clinical-stage biopharmaceutical company pioneering the discovery and development of a new generation of immuno-oncology therapeutics for patients, today announced that company management will participate in two upcoming conferences in December: 7 Th Annual Evercore HealthCONx Conference Format: Fireside chat and one-on-one investor meetings Date: Tuesday, December 3, 2024 Time:...

- EMA granted clearance to advance belrestotug 400mg + dostarlimab as recommended Phase 3 dose and activate GALAXIES Lung-301 clinical sites in the EU - Interim data from inupadenant Phase 2 A2A-005 in 2L NSCLC at ESMO-IO - Completed enrollment of EOS-984 Phase 1 monotherapy dose escalation and initiated dosing of EOS-984 + pembrolizumab combination - Pro forma cash and investment balance of $683.9 million as of September 30, 2024 expected to provide runway through 2027 across a number of...

WATERTOWN, Mass. and GOSSELIES, Belgium, Oct. 24, 2024 (GLOBE NEWSWIRE) -- iTeos Therapeutics, Inc. (Nasdaq: ITOS) (“iTeos”), a clinical-stage biopharmaceutical company pioneering the discovery and development of a new generation of immuno-oncology therapeutics for patients, today announced that preclinical, translational, and clinical data from inupadenant will be presented at the European Society for Medical Oncology Immuno-Oncology (ESMO-IO) Congress 2024, being held December 11-13, 2024...

- Clinically meaningful objective response rate (ORR) of 63.3-76.7% observed with belrestotug + dostarlimab combinations, with confirmed ORR (cORR) at ~60% for every dose - >30% cORR difference between belrestotug + dostarlimab vs dostarlimab monotherapy - Belrestotug + dostarlimab safety profile broadly consistent with known safety profile of checkpoint inhibitor combinations - GALAXIES Lung-301, global Phase 3 registration study, enrolling in same indication and setting - iTeos to host a...

WATERTOWN, Mass. and GOSSELIES, Belgium, Aug. 28, 2024 (GLOBE NEWSWIRE) -- iTeos Therapeutics, Inc. (Nasdaq: ITOS) (“iTeos”), a clinical-stage biopharmaceutical company pioneering the discovery and development of a new generation of immuno-oncology therapeutics for patients, today announced that company management will participate in two upcoming investor conferences in September: 2024 Wells Fargo Healthcare Conference Format: Fireside chat and one-on-one investor meetings Date: Wednesday,...